吡非尼酮
结缔组织增生
胰腺癌
骨膜炎
癌症研究
医学
肝星状细胞
癌症
转移
内科学
吉西他滨
病理
细胞外基质
特发性肺纤维化
生物
肺
细胞生物学
作者
Shingo Kozono,Kenoki Ohuchida,Daiki Eguchi,Naoki Ikenaga,Kenji Fujiwara,Lin Chen,Kazuhiro Mizumoto,Masao Tanaka
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2013-04-01
卷期号:73 (7): 2345-2356
被引量:159
标识
DOI:10.1158/0008-5472.can-12-3180
摘要
Abstract Pancreatic stellate cells (PSC), which are implicated in desmoplasia in pancreatic cancer, enhance the malignancy of cancer cells and confer resistance to established treatments. We investigated whether the antifibrotic agent pirfenidone can suppress desmoplasia and exert antitumor effects against pancreatic cancer. Primary PSCs were established from pancreatic cancer tissue obtained during surgery. In vitro, pirfenidone inhibited the proliferation, invasiveness, and migration of PSCs in a dose-dependent manner. Although supernatants of untreated PSCs increased the proliferation, invasiveness, and migration of pancreatic cancer cells (PCC), supernatants of pirfenidone-treated PSCs decreased these effects. Exposure to PCC supernatant increased the production of platelet-derived growth factor-A, hepatic growth factor, collagen type I, fibronectin, and periostin in PSCs, which was significantly reduced by pirfenidone. Mice were subcutaneously implanted with PCCs (SUIT-2 cells) and PSCs into the right flank and PCCs alone into the left flank. Oral administration of pirfenidone to these mice significantly reduced tumor growth of co-implanted PCCs and PSCs, but not of PCCs alone. Pirfenidone also decreased the proliferation of PSCs and the deposition of collagen type I and periostin in tumors. In mice with orthotopic tumors consisting of PCCs co-implanted with PSCs, pirfenidone suppressed tumor growth, reduced the number of peritoneal disseminated nodules, and reduced the incidence of liver metastasis. Pirfenidone in combination with gemcitabine more effectively suppressed orthotopic tumor growth compared with pirfenidone or gemcitabine alone. In conclusion, our findings indicate that pirfenidone is a promising antitumor agent for pancreatic cancer, owing to its suppression of desmoplasia through regulating PSCs. Cancer Res; 73(7); 2345–56. ©2013 AACR.
科研通智能强力驱动
Strongly Powered by AbleSci AI